Intratympanic gentamicin therapy for control of vertigo in unilateral Meniere's disease: a prospective, double-blind, randomized, placebo-controlled trial

Rolf J. Postema, Charlotte M. Kingma, Hero P. Wit*, Frans W. J. Albers, Bernard F. A. M. Van Der Laan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

73 Citations (Scopus)

Abstract

Conclusions. Intratympanic application of gentamicin is a relatively safe and efficient treatment for the reduction of complaints of vertigo attacks associated with Meniere's disease. The treatment also reduces the severity of the perceived aural fullness. Objective. To investigate the effectiveness of intratympanic gentamicin treatment in patients with unilateral Meniere's disease. Subjects and methods. In a prospective, double-blind, randomized, placebo-controlled clinical trial subjects scored vertigo complaints, aural fullness and tinnitus, before, during and up to 1 year after treatment. Hearing loss was monitored with pure tone audiometry. Results. Gentamicin treatment resulted in a significant reduction of the score for vertigo complaints and the score for perceived aural fullness. A small increase in hearing loss (average 8 dB) was measured in the gentamicin group.

Original languageEnglish
Pages (from-to)876-880
Number of pages5
JournalActa oto-Laryngologica
Volume128
Issue number8
DOIs
Publication statusPublished - 2008

Keywords

  • aminoglycosides
  • gentamicin
  • intratympanic
  • Meniere's disease
  • aural fullness
  • METAANALYSIS

Fingerprint

Dive into the research topics of 'Intratympanic gentamicin therapy for control of vertigo in unilateral Meniere's disease: a prospective, double-blind, randomized, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this